Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23487073 | 0.88 | CHRNB2 (0.47) | SMN1; SMN2CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL23323112 | 0.83 | CHRNB2 (0.51) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL13162085 | 0.83 | CHRNB4 (0.54) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL23323099 | 0.82 | HTR1B (0.48) | SMN1; SMN2CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL24775070 | 0.81 | SMN1; SMN2 (0.49) | SMN1; SMN2HCRTR2ALDH1A1L3MBTL1HCRTR1 | |
| SCHEMBL24775175 | 0.81 | SMN1; SMN2 (0.49) | SMN1; SMN2HCRTR2ALDH1A1L3MBTL1HCRTR1 | |
| SCHEMBL17513272 | 0.80 | HTR2A (0.44) | SMN1; SMN2CHRNB4CHRNA3ALDH1A1L3MBTL1 | |
| SCHEMBL23323087 | 0.79 | CHRNB4 (0.50) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL26772895 | 0.79 | CHRNB4 (0.50) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL12932568 | 0.76 | CHRNB2 (0.54) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
| WO-2021110102-A1 | METHODS OF CANCER TREATMENT USING BCL-2 INHIBITOR | BEIGENE, LTD. (KY) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021083135-A1 | Bcl-2 INHIBITORS | BEIGENE, LTD. (KY) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | SMN1; SMN2 1818/4885CHRNB2 4503/4885CHRNB4 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.